Crameri Reto, Rhyner Claudio
Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270 Davos, Switzerland.
Curr Opin Immunol. 2006 Dec;18(6):761-8. doi: 10.1016/j.coi.2006.09.001. Epub 2006 Sep 28.
Advances in genetic engineering and biotechnology, in parallel to increased understanding of disease processes and mechanisms of protective immunity, have facilitated the development of novel rational vaccination concepts for allergy. The spectrum ranges from utilizing recombinant proteins, peptides, new adjuvants, immunomodulatory therapy and DNA vaccines, to use of new application routes for both prophylaxis and treatment of allergic disease. New therapeutic concepts based on patient-tailored immunotherapy using recombinant allergens, anti-IgE and sublingual immunotherapies are slowly moving from the bench to the clinics. The additive value of new treatments above existing therapies must be, however, focused on the improvement of efficacy for long-term cure and increased patient compliance to warrant a broad applicability that has to compete with the symptomatic control of allergic and asthmatic diseases of currently available drugs.
随着基因工程和生物技术的进步，以及对疾病过程和保护性免疫机制的深入了解，新型合理的过敏疫苗接种概念得以发展。其范围涵盖利用重组蛋白、肽、新型佐剂、免疫调节疗法和DNA疫苗，以及采用新的应用途径来预防和治疗过敏性疾病。基于使用重组变应原、抗IgE和舌下免疫疗法的个体化免疫疗法的新治疗概念正逐渐从实验室走向临床。然而，新疗法相对于现有疗法的附加价值必须聚焦于提高长期治愈的疗效以及增强患者的依从性，以确保具有广泛的适用性，从而能够与目前可用药物对过敏性和哮喘性疾病的症状控制相竞争。
